Fig. 3

Lovastatin disrupted spatial and temporal gait parameters in Ube3a^+/+ mice. Sedating effects of lovastatin on metrics of gait in Ube3a^+/+ mice (WT). Lovastatin treatment at any dose did not affect (A) forelimb stance width, but all doses of lovastatin reduced the (D) hindlimb stance width. Both (B) forelimb stride length and (E) hindlimb stride length were significantly reduced when Ube3a^+/+ mice were treated with 100 mg/kg of lovastatin. No changes were observed in (C) forelimb stride frequency or (F) hindlimb stride frequency at any dose. Reductions in (G) forelimb stride duration and (J) hindlimb stride duration were present when treated with 100 mg/kg of lovastatin. No changes were observed at any dose of lovastatin in the (H) forelimb propulsion duration or (K) hindlimb propulsion duration. Finally, a reduction in (L) hindlimb stance duration was observed, following 100 mg/kg of lovastatin, but no changes were observed in the (I) forelimb stance duration. Number of mice tested for gait: WT Veh N = 10, 10 mg/kg N = 8, 30 mg/kg N = 8, 100 mg/kg N = 7; AS Veh N = 9, 10 mg/kg N = 10, 30 mg/kg N = 9, 100 mg/kg N = 10. * p < 0.05, two-way ANOVA, one–way ANOVA followed by Dunnett’s post hoc analysis